Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hyuntae Kim

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Journal of Medicinal Chemistry|April 24, 2023
Carbamate JNK3 Inhibitors Show Promise as Effective Treatments for Alzheimer's Disease: In Vivo Studies on Mouse ModelsJoonhong Jun, Hyungwoo Moon, Songyi Yang, et al.
Scientific Reports|December 23, 2022
Plasmon-exciton couplings in the MoS<sub>2</sub>/AuNP plasmonic hybrid structureHyuntae Kim, Jaeseung Im, Kiin Nam, et al.
Experimental & Molecular Medicine|November 22, 2018
A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximabSang-Kyu Lee, Yong-Hee Cho, Pu-Hyeon Cha, et al.
Oncotarget|November 12, 2016
KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancerYong-Hee Cho, Pu-Hyeon Cha, Saluja Kaduwal, et al.
EMBO Reports|November 11, 2018
β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3βSang-Kyu Lee, Woo-Jeong Jeong, Yong-Hee Cho, et al.
European Journal of Medicinal Chemistry|November 7, 2022
Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer's diseaseJoonhong Jun, Songyi Yang, Junghun Lee, et al.
ACS Central Science|September 29, 2025
The Martini 3 Lipidome: Expanded and Refined Parameters Improve Lipid Phase BehaviorKasper B Pedersen, Helgi I Ingólfsson, Daniel P Ramirez-Echemendia, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Journal of Medicinal Chemistry|April 24, 2023
Carbamate JNK3 Inhibitors Show Promise as Effective Treatments for Alzheimer's Disease: In Vivo Studies on Mouse ModelsJoonhong Jun, Hyungwoo Moon, Songyi Yang, et al.
Scientific Reports|December 23, 2022
Plasmon-exciton couplings in the MoS<sub>2</sub>/AuNP plasmonic hybrid structureHyuntae Kim, Jaeseung Im, Kiin Nam, et al.
Experimental & Molecular Medicine|November 22, 2018
A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximabSang-Kyu Lee, Yong-Hee Cho, Pu-Hyeon Cha, et al.
Oncotarget|November 12, 2016
KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancerYong-Hee Cho, Pu-Hyeon Cha, Saluja Kaduwal, et al.
EMBO Reports|November 11, 2018
β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3βSang-Kyu Lee, Woo-Jeong Jeong, Yong-Hee Cho, et al.
European Journal of Medicinal Chemistry|November 7, 2022
Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer's diseaseJoonhong Jun, Songyi Yang, Junghun Lee, et al.
ACS Central Science|September 29, 2025
The Martini 3 Lipidome: Expanded and Refined Parameters Improve Lipid Phase BehaviorKasper B Pedersen, Helgi I Ingólfsson, Daniel P Ramirez-Echemendia, et al.
Pageof 6